Grifols vs Teva Pharmaceutical Industries
GRFS and TEVA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How GRFS and TEVA compare
Grifols grew revenue faster over the last twelve months (4.3% versus −15.2% for Teva Pharmaceutical Industries).
Grifols keeps more of each dollar of sales as profit, with a net margin of 5.3% compared with 5.0% at Teva Pharmaceutical Industries.
Grifols scores higher on the StockData Score (9 against 7 for Teva Pharmaceutical Industries), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | GRFS | TEVA |
|---|---|---|
| Size and price | ||
| Market cap | – | $48.3B |
| Share price | $8.10 | $41.47 |
| Change, 1 year | −13.7% | 110% |
| Change, 5 years | −33.7% | 354% |
| Beta (5Y) | 0.91 | 0.99 |
| Employees | 1,613 | 34K |
| StockData Score | ||
| Total score | 9 (better) | 7 |
| Valuation score | 0 | 0 |
| Growth score | 2 | 2 |
| Performance score | 4 | 4 |
| Health score | 3 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 69.1× |
| P/S | – | 3.4× |
| P/B | – | 6.2× |
| EV/EBITDA | – | 19.0× |
| P/FCF | – | 35.8× |
| FCF yield | – | 2.8% |
| Fair value | – | $18.65 |
| Margin of safety | – | −122% |
| Growth | ||
| Revenue growth (TTM) | 4.3% (better) | −15.2% |
| Revenue growth, 5Y average | 7.1% (better) | 0.71% |
| Net income growth (TTM) | 156% | – |
| EPS growth (TTM) | 157% | – |
| EPS growth, 5Y average | −8.1% | – |
| Profitability | ||
| Gross margin | 38.0% | 64.4% (better) |
| Operating margin | 16.5% (better) | 11.4% |
| Net margin | 5.3% (better) | 5.0% |
| FCF margin | 10.4% (better) | 9.6% |
| Return on equity | 7.2% | 9.7% (better) |
| Return on invested capital | 14.6% | 23.0% (better) |
| Financial health | ||
| Debt / equity | 0.41 (better) | 0.58 |
| Net debt / EBITDA | 0.79 | 0.33 (better) |
| Interest coverage | 2.0× | – |
| Current ratio | 2.51 (better) | 0.88 |
| Altman Z-score | – | 0.84 |
| Piotroski F-score | 5 | 8 (better) |
| Dividends and buybacks | ||
| Payout ratio | 31.8% | – |
| Shareholder yield | – | 0.00% |
| Ownership | ||
| Held by institutions | 20.8% | – |
| Held by insiders | 0.00% | 0.43% |
| Insider net buying, 12 months | – | −$113M |
| Short interest, % of float | – | 2.6% |
Go deeper
- GRFS stock overview
- GRFS income statement
- GRFS valuation and score
- TEVA stock overview
- TEVA income statement
- TEVA valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.